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Abstract
Introduction: The aim of this study was to verify if genetic factors influence the short- and long-term therapeutic responses to oestropro-
gestagen (OP) therapy, implemented in girls with functional hypothalamic amenorrhoea (FHA) in order to improve their bone mineral 
density (BMD).
Material and methods: The study included 78 FHA girls who underwent a four-year sequential OP therapy with 17-beta oestradiol and 
didrogesterone. Changes in the lumbar spine BMD were determined at the end of the therapy and six years after its discontinuation, and 
analysed in regards to PvuII and XbaI polymorphisms of oestrogen receptor-alpha gene, BsmI polymorphism of vitamin D3 receptor gene, 
and Sp1 polymorphism of the type-1 collagen gene.
Results: After four years of OP therapy, a significant increase in BMD was documented in the studied group. Follow-up densitometry 
performed six years after completing the therapy revealed a significant decrease in BMD level; nonetheless, the values of this parameter 
were still significantly higher compared to pretreatment level. Neither the particular polymorphisms nor their combinations influenced 
the relative change in BMD at the end of the therapy and after a six-year follow-up.
Conclusions: Variability of genes involved in oestrogen, vitamin D3 and collagen metabolism does not influence the short- and long-term 
results of OP therapy in girls with FHA. (Endokrynol Pol 2012; 63 (6): 420–426)
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Streszczenie
Wstęp: Celem niniejszej pracy było ustalenie, czy czynniki genetyczne wpływają na bliskie i odległe wyniki terapii estrogenowo-proge-
stagenowej, zastosowanej w celu normalizacji gęstości mineralnej kości (BMD, bone mineral density) u dziewcząt z brakiem miesiączki typu 
funkcjonalnego (FHA, functional hypothalamic amenorrhoea).
Materiał i metody: Badaniem objęto 78 dziewcząt z FHA poddanych 4-letniej sekwencyjnej terapii estrogenowo-progestagenowej 
17-beta estradiolem i didrogesteronem. Wielkość zmian w BMD odcinka lędźwiowego kręgosłupa oceniano po zakończeniu terapii oraz 
6 lat później. Uzyskane wyniki analizowano w odniesieniu do występowania u pacjentek: polimorfizmów PvuII i XbaI genu receptora 
estrogenowego alfa, polimorfizmu BsmI genu receptora witaminy D3, oraz polimorfizmu Sp1 genu kolagenu typu 1.
Wyniki: Po 4 latach terapii estrogenowo-progestagenowej w badanej grupie odnotowano znamienny wzrost BMD. Kontrolne badanie 
densytometryczne wykonane po 6 latach od zakończenia leczenia wykazało znamienny spadek poziomu BMD; tym niemniej, wartości 
tergo parametru były wciąż istotnie wyższe w porównaniu z poziomem przed rozpoczęciem terapii. Na względną zmianę poziomu 
BMD bezpośrednio po zakończeniu leczenia oraz 6 lat później nie wpływało w sposób istotny występowanie żadnego z analizowanych 
polimorfizmów ani ich kombinacji.
Wnioski: Zmienność genów zaangażowanych w przemiany estrogenów, witaminy D3 i kolagenu nie wpływa na bliskie i odległe wyniki 
terapii estrogenowo-progestagenowej u dziewcząt z FHA. (Endokrynol Pol 2012; 63 (6): 420–426)
Słowa kluczowe: gęstość mineralna kości, brak miesiączki typu funkcjonalnego, terapia hormonalna, osteoporoza
Introduction
Functional hypothalamic amenorrhoea (FHA) is a psy-
chosomatic disorder causing impairment in the ovarian 
oestrogen synthesis. According to the few available 
reports, the prevalence of FHA in developed countries 
is estimated at between 2.6% and 8.5% [1].
Besides disrupting sexual maturation, oestrogen 
deficiency affects negatively osteogenesis in FHA 
girls. This unfavourable effect results from antiresorp-
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tive and anabolic influences of oestrogens on skeletal 
tissue [2, 3].
Consequently, hormonal substitution constitutes 
the accepted direction in the management of FHA 
patients; this treatment is aimed at the gradual nor-
malisation of the hypothalamic-pituitary-ovarian axis 
function [4, 5]. The effectiveness of this approach, in 
terms of bone mass levels in FHA girls, has been the 
subject of several studies [6–11] including research 
conducted by our group [12–14]. In these studies, 
implementation of long-term oestroprogestagen (OP) 
therapy was reflected by an increase in bone mineral 
density (BMD) of replacement patients. Although our 
previous experiments revealed a significant variabil-
ity in the degree of therapeutic responses to OP [13], 
we failed to confirm the influence of genetic factors 
on the therapeutic outcomes [12, 14].
One should remember however, that both of the 
abovementioned studies examined the effects of 
genetic factors on bone mineral density determined 
at the end of hormonal treatment: consequently, we 
were not able to analyse long-term changes in BMD 
that occurred with time after discontinuation of the 
therapy. Thus, when data from long-term follow-up 
of the same patients became available, we decided 
to verify if genetic factors influence the long-term 
outcomes of hormonal treatment with regard to bone 
mineral density. In order to analyse the entire genetic 
background of osteogenesis, aside from testing the 
previously studied polymorphisms of ER-alpha and 
VDR genes, the variability of the type-1 collagen 
(COLIA1) gene was also considered. Moreover, ge-




The study included 78 girls with FHA, aged 16 and 17, 
who were treated at the Department of Gynaecology, 
University of Medical Sciences in Poznan (Poland) 
between 2004 and 2009, and followed-up for six years 
after completing the therapy. Detailed characteristics 
of the study participants are summarised in Table I. All 
procedures were approved by the Local Ethics Com-
mittee of the University of Medical Sciences in Poznan. 
Both the subjects and their parents gave their informed 
consent before the start of any procedure.
Qualification criteria for this study included: 
1) at least six months of amenorrhoea preceded by at 
least three years of oligomenorrhoea; and 2) psycho-
logical problems confirmed by a clinical psychologist. 
The exclusion criteria, based on medical history and 
standardised questionnaire survey [13], included the 
following: 1) polycystic ovary syndrome, congenital 
adrenal hyperplasia or premature ovarian failure; 
2) low birth weight or preterm birth; 3) at least one 
confirmed episode of eating disorders; 4) malnu-
trition during childhood or puberty; 5) history of 
impaired growth and body mass gain; 6) extensive 
participation in sports that may have influenced 
bone mineralisation; 7) metabolic disorders that may 
be associated with decreased bone mineralisation; 
8) prolonged use of stimulants or drugs that may af-
fect bone metabolism; 9) familial history of osteopo-
rosis; and 10) incomplete 10-year follow-up (cessation 
of treatment due to medical indications or because of 
other reasons, failure to return for the follow-up visit).
Intervention
The patients underwent a four-year sequential OP 
therapy with a preparation which included the natural 
female sex hormone 17-beta oestradiol (2 mg from the 
2nd to 25th day of the menstrual cycle) and didrogester-
one (10 mg from the 16th to the 25th day of the menstrual 
cycle). The goal of the treatment was the resumption of 
regular menstrual bleeding and, therefore, the therapy 
was continued for a period of four years. In addition 
to hormonal treatment, patients were encouraged to 
modify their lifestyles and dietary habits. They were 
prescribed calcium and vitamin D3 preparations at 
individual doses adjusted for their dietary content and 
season of the year. Moreover, regular physical activity 
(15 minutes of recreational gymnastics twice a day) 
was recommended. During the follow-up visits, all 
the patients declared that they had adhered to these 
recommendations.
Densitometry
BMD of the lumbar spine (L2–L4) was measured prior 
to the therapy, after each 12 months of treatment, and 
six years after its discontinuation. BMD measurements 
were performed based on the DXA method (GE Lunar 
Prodigy Advance, Madison, WI, USA; software enCORE 
version 8.8), using an automatic scan mode. Results 
were presented as absolute values (g/cm2) and relative 
changes (%).
Testing for genetic polymorphisms
Samples of venous blood (10 mL) were collected from 
every patient and stored in EDTA anticoagulant in 
order to extract genomic DNA from peripheral blood 
mononuclear cells using a non-enzymatic inorganic 
method [15]. PvuII and XbaI polymorphisms of oestro-
gen receptor-alpha gene [16], BsmI polymorphism of 
vitamin D3 receptor gene [17], and Sp1 polymorphism 
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Statistical evaluation of the results
Continuous variables were presented as arithmetic 
means and their standard deviations (SD); their normal 
distribution was tested using the Shapiro-Wilk test. 
Arithmetic means of continuous variables between 
groups of patients determined based on certain geno-
types and their combinations were compared with 
ANOVA and the Tukey post-hoc test. The significance of 
time changes in analysed variables was tested with the 
Friedman ANOVA. Additionally, the effects of studied 
gene polymorphisms on therapeutic responses were 
verified in a logistic regression model. All calculations were 
performed using Statistica 8 (StatSoft®, Poland) software, 
and statistical significance was defined as p ≤ 0.05.
Results
All patients resumed spontaneous menstrual bleeding 
as a result of hormonal treatment. After four years of OP 
therapy, a significant increase in BMD was documented 
in the studied group. However, follow-up densitom-
etry performed six years after completing the therapy 
revealed a significant decrease in BMD level; nonethe-
less, the values of this parameter were still significantly 
higher compared to the pretreatment level (Table II).
None of the single gene polymorphisms was re-
vealed to influence significantly the relative change in 
BMD level after four years of the therapy. Furthermore, 
the effects of polymorphisms on treatment outcomes 
were also not observed in multivariate analysis (Table 
III) and subanalysis of ER-alpha gene haplotypes.
Based on the median relative change in BMD after 
four years of the therapy (21.9%), two subgroups of 
patients with a different therapeutic response were 
distinguished (relative increase in BMD ≤ 22%, n = 40 
v. > 22%, n = 38). The single polymorphisms that were 
analysed were not found to determine a poorer thera-
peutic response (VDR: OR = 1.09, 95% CI 0.66–1.81, 
p = 0.718; XbaI: OR = 1.07, 95% CI 0.65–1.77, p = 0.782; 
PvuII: OR = 1.34, 95% CI 0.75–2.37, p = 0.320; COLIA1: 
OR = 0.83, 95% CI 0.28–2.46, p = 0.728). Furthermore, 
the significant effects of variability in studied genes were 
not observed in multivariate analysis (VDR: OR = 1.09, 
95% CI 0.66–1.83, p = 0.727; XbaI: OR = 0.77, 95% CI 
0.35–1.71, p = 0.519; PvuII: OR = 1.69, 95% CI 0.69–4.14, 
p = 0.251; COLIA1: OR = 0.83, 95% CI 0.28–2.51, p = 
= 0.739) and in subanalysis of ER-alpha gene haplotypes 
(XbaI: OR = 0.75, 95% CI 0.34–1.65, p = 0.470; PvuII: OR 
= 1.71, 95% CI 0.70–4.21, p = 0.237).
Moreover, variability of any single gene did not 
modulate significantly the level of relative decrease in 
BMD observed six years after the discontinuation of 
the therapy. Significant effects of variability in studied 
genes on long-term therapeutic outcomes were also not 
documented in multivariate analysis (Table IV), or in su-
banalysis of the influences of ER-alpha gene haplotypes.
Based on median decrease in BMD six years after the 
completion of the therapy (5.8%), two groups of patients 
Table I. Detailed characteristics of the study participants prior to OP therapy (year 0), at its completion (year 4), and six years 
thereafter (year 10); all values expressed as mean ± SD
Tabela I. Szczegółowe charakterystyki uczestniczek badania przed rozpoczęciem terapii OP (0 lat), po jej zakończeniu (4 lata) 
oraz sześć lat później (10 lat); wszystkie wartości przedstawione jako średnie ± SD
Parameter Year 0 Year 4 Year 10
Age (years) 16.70 ± 1.16 20.70 ± 1.16 26.67 ± 1.14
Height [cm] 162.27 ± 6.63 164.18 ± 6.38 165.27 ± 7.06
Weight [kg] 49.21 ± 6.23 54.31 ± 4.52 57.36 ± 6.45
BMI [kg/m2] 18.68 ± 2.05 20.19 ± 1.80 21.33 ± 2.40
BMI — body mass index
Table II. BMD levels prior to OP therapy (year 0), at its completion (year 4), and six years thereafter (year 10)
Tabela II. Poziom BMD przed rozpoczęciem terapii OP (0), po jej zakończeniu (4 lata) oraz sześć lat później (10 lat)
Year BMD Change in BMD (%)
Mean SD Range Mean SD range
0 0.816 0.088 0.548–0.987 – – –
4 0.998* 0.097 0.799–1.172 23.3 14.3 (–) 1.5–63.3
10 0.944** 0.109 0.646–1.155 –5.3 7.8 (–) 34.1–16.7
*,**significantly different compared to other periods (p < 0.001, Friedman ANOVA); BMD — bone mineral density
423













with different long-term outcomes were distinguished 
(relative decrease in BMD ≤ 6%, n = 41 v. > 6%, n = 37). 
We did not observe negative effects of any single poly-
morphism on long-term therapeutic response (VDR: OR 
= 1.16, 95% CI 0.70–1.93, p = 0.551; XbaI: OR = 1.01, 95% CI 
0.61–1.67, p = 0.959; PvuII: OR = 0.96, 95% CI 0.54–1.70, 
p = 0.893; COLIA1: OR = 1.44, 95% CI 0.48–4.37, p = 0.510). 
Significant effects of studied genes’ variability were also 
not confirmed in multivariate analysis (VDR: OR = 1.16, 
95% CI 0.70–1.93, p = 0.560; XbaI: OR = 1.09, 95% CI 
0.50–2.36, p = 0.829; PvuII: OR = 0.89, 95% CI 0.37–2.14, 
p = 0.796; COLIA1: OR = 1.41, 95% CI 0.46–4.32, p = 0.540) 
and in subanalysis of ER-alpha gene haplotypes 
(XbaI: OR = 1.09, 95% CI 0.51–2.35, p = 0.816; PvuII: 
OR = 0.89, 95% CI 0.37–2.12, p = 0.792).
Discussion
The results of this study revealed that the administra-
tion of four-year hormonal therapy is reflected by an 
improvement in BMD of FHA girls. While the control 
densitometry performed six years after the completion 
of the treatment documented a significant decrease in 
bone mineral density, this parameter still remained sig-
nificantly higher compared to its pretreatment values.
We have previously revealed that directly after com-
pleting the hormonal treatment, BMD of FHA patients is 
still lower than in healthy peers from the control group; 
furthermore, we have documented inhomogeneous 
therapeutic response of FHA girls to hormonal therapy 
[13]. Consequently, we have proposed that the degree 
Table III. Effects of VDR, XbaI, PvuII and COLIA1 gene polymorphisms on relative change in BMD observed after four years 
of OP therapy (ANOVA, p = 0.162)
Tabela III. Wpływ polimorfizmów VDR, XbaI, PvuII i COLIA1 na względną zmianę poziomu BMD po czterech latach terapii 
OP (ANOVA, p = 0,162)
Genotype n Change in BMD (%)
VDR XbaI PvuII COLIA1 Mean SD
bb xx Pp SS 4 30.3 8.9
bb xx Pp Ss 1 29.1 –
bb xx PP SS 3 22.1 8.6
bb xx Pp SS 2 19.3 2.0
bb XX PP SS 8 18.5 9.2
bb Xx Pp SS 1 39.7 –
bb Xx PP SS 5 12.9 12.7
bb Xx Pp SS 3 41.2 20.3
bb Xx Pp Ss 2 22.8 7.3
BB xx Pp Ss 1 31.2 –
BB xx Pp SS 3 22.1 5.8
BB xx Pp Ss 2 33.1 2.5
BB xx PP SS 3 19.5 16.8
BB XX PP Ss 1 0.5 –
BB Xx Pp SS 4 25.2 22.1
BB Xx Pp Ss 1 45.1 –
Bb xx Pp Ss 1 25.6 –
Bb xx Pp SS 9 12.4 9.0
Bb xx Pp Ss 3 25.4 17.4
Bb xx PP SS 4 31.2 22.9
Bb XX PP SS 4 18.4 3.2
Bb XX Pp SS 1 8.5 –
Bb Xx PP Ss 1 45.8 –
Bb Xx Pp SS 9 29.3 16.4
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of therapeutic response is at least partially determined 
by polymorphism of genes involved in the control of 
osteogenesis. However, our further studies have not 
unequivocally confirmed the role of oestrogen receptor-
alpha gene polymorphism in this setting [14], and have 
excluded the involvement of vitamin D3 receptor gene 
variability in this process [12]. This study has provided 
further evidence that genetic factors have a minor 
impact on the normalisation of bone mineral density 
impaired due to psycho-emotional and secondary hor-
monal disorders. The level of long-term therapeutic 
response to hormonal treatment was not modulated 
either by polymorphisms in oestrogen receptor-alpha 
gene or by the variability of genes encoding vitamin D3 
receptor and collagen type-1.
A thorough search through the literature did not 
yield any published research analysing the relationship 
between the genetic factors and the degree of changes in 
bone mineral density induced by hormonal treatment. 
Furthermore, a review of literature dealing with the 
genetic determinants of bone mineral density in women 
revealed marked discrepancies between the results of 
previous studies. In one study, pre-pubertal girls with 
the PP PvuII genotype of ER-alpha gene had a nearly 
5-fold higher relative risk of fractures and a significantly 
lower BMD of the spine compared to their peers with 
the pp genotype [19]. However, studies of postmeno-
pausal women using hormone replacement therapy 
did not distinguish which of the genetic variants of 
ER-alpha is a predictor of worse therapeutic response 
Table IV. Effects of VDR, XbaI, PvuII and COLIA1 gene polymorphisms on relative change in BMD observed six years after 
completing OP therapy (ANOVA, p = 0.083)
Tabela IV. Wpływ polimorfizmów VDR, XbaI, PvuII i COLIA1 na względną zmianę poziomu BMD po sześciu latach od 
zakończenia terapii OP (ANOVA, p = 0,083)
Genotype n Change in BMD (%)
VDR XbaI PvuII COLIA1 Mean SD
bb xx Pp SS 4 –9.3 6.1
bb xx Pp Ss 1 1.5 –
bb xx PP SS 3 –5.3 3.5
bb xx Pp SS 2 -8.8 8.2
bb XX PP SS 8 –6.7 6.2
bb Xx Pp SS 1 –9.0 –
bb Xx PP SS 5 –7.5 5.3
bb Xx Pp SS 3 –10.3 9.2
bb Xx Pp Ss 2 –13.1 5.5
BB xx Pp Ss 1 0.0 –
BB xx Pp SS 3 0.5 12.0
BB xx Pp Ss 2 –7.5 8.5
BB xx PP SS 3 –8.0 6.0
BB XX PP Ss 1 10.0 –
BB Xx Pp SS 4 –1.4 9.5
BB Xx Pp Ss 1 –5.2 –
Bb xx Pp Ss 1 –34.1 –
Bb xx Pp SS 9 –0.4 10.4
Bb xx Pp Ss 3 –5.1 2.4
Bb xx PP SS 4 –6.3 4.6
Bb XX PP SS 4 –3.9 3.8
Bb XX Pp SS 1 –9.6 –
Bb Xx PP Ss 1 –1.4 –
Bb Xx Pp SS 9 –5.0 5.4
Bb Xx Pp Ss 2 –0.8 7.7
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in the context of bone mineral density normalisation. 
Depending on the study, either the xxPP haplotype 
[20, 21] or XX Xbal [22, 23] and PP Pvull genotypes [23] 
were found to be the negative predictive factors. Fur-
thermore, no relationships between ER-alpha genotype 
and the response to hormonal treatment were observed 
by several authors [24–26].
Similar discrepancies pertain to the effects of the 
VDR receptor gene polymorphism on BMD level. The 
variability of the different sites at intron 8/exon 9 of 
this gene, BsmI, ApaI and TaqI, and the FokI site at exon 
2.3, was analysed during previous experiments with 
various restriction enzymes. The most unambiguous 
data regarding the involvement of the VDR gene in the 
determination of bone mineral density pertains to the 
polymorphism of the FokI region. Several authors have 
observed that the FF genotype is associated with better 
calcium absorption, while the ff genotype frequently co-
exists with bone mass deficiencies. However, the existing 
evidence of the role of BsmI polymorphism, analysed in 
this study, is conflicting. Some authors have observed 
that the highest BMD levels are found among carriers 
of homozygous genotypes of this polymorphism, BB 
or bb, while others have shown the Bb genotype to be 
predictive for high bone mineral density [17, 27–32].
The results of previous studies of the role of Sp1 
polymorphism of COLIA1 suggest that variability in this 
region of collagen type-1 gene can influence bone mass, 
particularly in the context of osteoporotic risk in old age. 
However, the results of the multicentre GENOMOS 
study suggest that such a relationship is not directly 
linked to BMD [33].
Interpreting the results of our research, one should 
consider the potential limitations related to the inter-
ventional character of this study. The first potential 
flaw pertains to the relatively small sample size related 
to the fact that some participants did not complete the 
four-year course of the therapy and some patients failed 
to attend follow-up visits. Another potential limita-
tion is the lack of a randomly selected control group 
consisting of FHA girls who did not receive hormonal 
treatment and/or were subjected to a different type of 
intervention. Due to this limitation, we were unable to 
distinguish to what extent the observed improvement 
in bone mineral density resulted from spontaneous 
normalisation of osteogenesis.
Nonetheless, these aforementioned flaws did not 
constitute an obstacle to attaining the principal objec-
tive of this study. Both our findings and the literature 
evidence suggest limited clinical application of genetic 
tests in determining potential predictors of bone mass 
response to hormonal treatment. In view of the current 
evidence, we are not able to determine whether genetic 
factors per se do not affect osteogenesis in adolescent 
girls, or whether the lack of such dependence can be 
attributed to the shortcomings of the currently used 
tests or incorrect interpretation of their results. Although 
this distinction is vital from the scientific point of view, 
it is of lesser importance for clinical practitioners. From 
the clinical viewpoint, the principal implication of the 
current and previous studies is the negligible usefulness 
of genetic predisposition analysis in planning activities 
aimed at normalisation of bone mass in FHA girls. In 
view of the current evidence, the optimal approach to 
this group of patients includes the administration of 
hormonal therapy, along with modification of external 
factors that can modulate the level of bone mass — par-
ticularly supplementation with vitamin D3 and calcium 
preparations, and properly adjusted levels of regular 
physical activity [34].
Conclusions
This study revealed that the variability of genes in-
volved in oestrogen, vitamin D3 and collagen metabo-
lism does not influence the short- and long-term results 
of OP therapy in girls with FHA.
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